Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Neurosci. Author manuscript; available in PMC Apr 20, 2011.
Published in final edited form as:
PMCID: PMC2987617
NIHMSID: NIHMS246487

Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding

Abstract

Endocannabinoids, particularly 2-arachidonoyl glycerol (2-AG), impact the directional turning and motility of a developing axon by activating CB1 cannabinoid receptors (CB1Rs) in its growth cone. Recent findings posit that sn-1-diacylglycerol lipases (DAGLα/β) synthesize 2-AG in the motile axon segment of developing pyramidal cells. Coincident axonal targeting of CB1Rs and DAGLs prompts the hypothesis that autocrine 2-AG signaling facilitates axonal outgrowth. However, DAGLs alone are insufficient to account for the spatial specificity and dynamics of 2-AG signaling. Therefore, we hypothesized that local 2-AG degradation by monoacylglycerol lipase (MGL) must play a role. We determined how subcellular recruitment of MGL is temporally and spatially restricted to establish 2-AG’s signaling competence during axonal growth. MGL is expressed in central and peripheral axons of the fetal nervous system by embryonic day 12.5. MGL coexists with DAGLα and CB1Rs in corticofugal axons of pyramidal cells. Here, MGL and DAGLα undergo differential axonal targeting with MGL being excluded from the motile neurite tip. Thus, spatially-confined MGL activity generates a 2-AG-sensing microdomain and configures 2-AG signaling to promote axonal growth. Once synaptogenesis commences, MGL disperses in stationary growth cones. MGL’s axonal polarity is maintained by differential proteasomal degradation since inhibiting the ubiquitin proteasome system also induces axonal MGL redistribution. Since MGL inactivation drives a CB1R-dependent axonal growth response we conclude that 2-AG may act as a focal protrusive signal for developing neurons and whose regulated metabolism is critical for attaining correct axonal complexity.

Keywords: axon, cortex, endocannabinoid, forebrain, signaling domain, thalamus

Introduction

Acquisition of a characteristic neuronal cytoarchitecture and connectivity pattern relies on signaling cassettes whose coordinated expression and temporal interplay drive neuronal identification in the developing nervous system (Fishell and Hanashima, 2008; Ibanez and Ernfors, 2007). Endocannabinoid (eCB) signaling affects neural state change decisions either directly (Berghuis et al., 2007) or by interacting with neurotrophin (Maison et al., 2009) or cytokine signaling (Zorina et al., 2010). The discovery that neuronal lineage commitment and axonal polarization coincide with CB1 cannabinoid receptor (CB1R) expression (Begbie et al., 2004; Coutts et al., 2001; Mulder et al., 2008; Berghuis et al., 2007) and persist in the presence of a particularly high 2-arachidonoyl glycerol (2-AG) tone (Berrendero et al., 1999) prompted the view that downstream signaling from CB1Rs diversifies the cellular outcome of eCB signaling in developing neurons (Bromberg et al., 2008). In contrast, the developmental dynamics of 2-AG signaling entailing coordinated expression of the 2-AG synthesizing and degrading enzymes sn-1-diacylglycerol lipases α/β (DAGLα/β) (Bisogno et al., 2003) and monoacylglycerol lipase (MGL) (Dinh et al., 2002), respectively, remain largely unexplored. Understanding spatial and temporal constraints of the metabolic network responsible for regulating 2-AG bioavailability is necessary to appreciate 2-AG’s physiological significance in the hierarchy of integrative signaling networks that determine neuronal identity.

The process of directional axonal growth relies on multimodal communication between individual axons whilst they navigate through brain microdomains presenting a spectrum of attractive and repulsive guidance cues (Xiang et al., 2002). eCB signaling is a novel mechanism positioned to facilitate corticofugal axon development (Watson et al., 2008) since axonal targeting of DAGLα/β can generate cell-autonomous 2-AG microgradients engaging CB1Rs in motile growth cones (Bisogno et al., 2003). Alternatively, 2-AG released from corticofugal axons can act as a paracrine guidance signal and limit premature dispersion of axon collaterals by establishing permissive pathfinding corridors (Mulder et al., 2008). Accordingly, impaired CB1R function during growth cone navigation presents an aberrant axon fasciculation and post-synaptic target selection phenotype (Watson et al., 2008; Berghuis et al., 2007). However, the above model is incomplete as it neither identifies an axonal domain whose cytoskeletal dynamics are particularly sensitive to eCBs nor explains how eCB actions are restricted to the distal motile axon segment to drive its unidirectional extension. Therefore, an adequate mechanistic concept must imply focal 2-AG-degrading activity, likely produced by MGL, known to degrade 85–90% of 2-AG in adult brain homogenates (Blankman et al., 2007), to restrict 2-AG signaling to the navigating growth cone and away from the consolidating neurite shaft.

Here, we explored the developmental dynamics of MGL expression and its spatial relationship with CB1R and DAGLα/β during forebrain development. We identify a metabolic regulatory network allowing both autocrine and paracrine 2-AG signaling to operate in developing brain with CB1R being dispensable to regulate the expression and correct axonal targeting of both MGL and DAGLα. We directly implicate 2-AG signaling in axon development by demonstrating that site-directed MGL inactivation triggers a CB1R-dependent axonal growth response.

Materials and methods

Animals and tissue preparation

Mouse embryos (n ≥ 6/time point, n ≥ 2 pregnancies/analysis) were obtained from time-mated C57Bl6/N, GAD67-GFP+ (Δneo) (Tamamaki et al., 2003), tau-EGFP (Tucker et al., 2001) or CB1R−/− and corresponding CD1 wild-type mice (Ledent et al., 1999) at embryonic days (E)12.5–18.5. Whole brains were immersion fixed in 4% paraformaldehyde (PFA) in Na-phosphate buffer (PB, 0.1M, pH7.4) overnight. Tissue samples were cryoprotected in 30% sucrose in physiological saline for at least 48h prior to cryostat sectioning (16 µm thickness) and thaw-mounting on SuperFrost+ glass slides. Experiments conformed to the 86/609/EEC directive and were approved by the Home Office of the United Kingdom.

Histochemical expression profiling and quantitative microscopy

Basic concepts of forebrain development are discussed in Supplemental Information (SI). Serial sections were processed according to published protocols (Berghuis et al., 2007) with select combinations of primary antibodies (Supplemental Table 1A,A1). Hoechst 35,528 (Sigma), a nuclear dye, has been applied to reveal tissue architecture. Antibodies raised against CB1R, its C-terminal interacting protein 1a isoform (CRIP1a), DAGLα, and MGL (Twitchell et al., 1997; Uchigashima et al., 2007; Yoshida et al., 2006; Straiker et al., 2009) were independently validated by at least two of the following methods: (i) preadsorption of primary antibodies with their corresponding fusion protein (5 µg/ml) in vitro and/or in vivo, (ii) co-localization with hemagglutinin (HA)-tagged target protein heterologously expressed in HEK293 cells, (iii) lack of staining in corresponding null mice (data not shown for DAGLα) or (iv) identical staining patterns by multiple antibodies recognizing distinct epitopes within a target protein (Supplemental Figs. 1–3).

Sections were inspected and images were acquired on a 710LSM confocal laser-scanning microscope (Zeiss) equipped to separate emission signals through spectral detection and unmixing. Emission spectra for each dye was limited as follows: Hoechst (420–485 nm), Cy2 (505–530 nm), Cy3 (560–610 nm), and Cy5 (640–720 nm). Image surveys were generated using the tile scan function with optical zoom ranging from 0.6× to 1.5× at 10× primary magnification (objective: EC Plan-Neofluar 10×/0.30). Images were processed using the ZEN2009 software (Zeiss). Multi-panel figures were assembled in CorelDraw X3 (Corel Corp.).

Co-localization was defined as immunosignals being present without physical signal separation in ≤1.0-µm optical slices at 40× (Plan-Neofluar 40×/1.30) or 63× (Plan-Apochromat 63×/1.40) primary magnification (Mulder et al., 2009). The co-localization utility of the ZEN2009 software package was used to determine i) the relative area occupancy for each fluorochrome, defined as the density of fluorescence pixels normalized to a 1 µm2 surface area, ii) the colocalization coefficient of CB1R vs. MGL immunoreactivities in the cortical plate or thalamus, expressed as the relative number of colocalizing pixels in one channel as compared to the total number of pixels above threshold in another channel, and iii) Pearson’s correlation coefficient defining the intensity distribution within colocalizing regions (ranging from −1 to +1 with 0 indicating no correlation).

Pre-embedding electron microscopy

E13-13.5 mouse embryos were decapitated and brains were immersion fixed overnight (Morozov et al., 2009). Pre-embedding immunoperoxidase labeling to localize CB1Rs in coronal vibratome sections (100 µm) was performed with specimens subsequently osmificated and contrasted (Morozov et al., 2009).

In utero electroporation

At E11.5, in utero electroporation was carried out as described (Torii et al., 2009) by injecting a DNA solution containing a pCAGGS-EGFP plasmid at a concentration of 0.5 mg/ml using a pulled glass capillary. Electroporation was performed using a BTX ECM830 Square Wave Electroporator with 5 electric pulses at 25 V for 50 ms each with 950 ms intervals (Morozov et al., 2009). Dams were decapitated after 3–6 days, embryos were removed, and inspected for EGFP fluorescence (Stemi SV11 Apo, Zeiss). EGFP-expressing brains were immersion fixed, sectioned, and CB1Rs were localized as above.

Neuronal cultures, immunocytochemistry and morphometry

Embryonic cortices and hippocampi were dissected at E14.5 or E16.5. Cells were dissociated by trypsin (0.1%) and plated on coverslips coated with poly-D-lysine (PDL; Sigma). Cultured neurons (30 – 50,000 cells/well in 24-well plates) were maintained for 2 or 4 days in vitro (DIV) as described (Mulder et al., 2008). Lactacystin (20 µM, Tocris) an irreversible inhibitor of the 20S proteasome, tetrahydrolipstatin (THL, 1 µM, Sigma) and O-3841 (1 µM) (Bisogno et al., 2006), DAGL inhibitors; JZL184 (100 nM, Cayman) (Long et al., 2009) and URB 602 (5 µM, Cayman) (King et al., 2007), MGL inhibitors; and O-2050 (200 nM, a neutral CB1R antagonist; Tocris) were added to modulate axonal MGL distribution and growth rates as well as to induce growth cone collapse. Immunocytochemistry was performed with select combinations of primary antibodies (Supplemental Table 1) (Berghuis et al., 2007). The Dotti staging method was used to define axon development (Dotti et al., 1988). Images of cortical neurons and their axons were captured by means of laser-scanning microscopy (model 710LSM, Zeiss). Neurite length and the surface area of individual growth cones were determined at the time points indicated (Fig. 9) by analyzing calibrated images in the LSM5 image browser software module (v. 3.2.0.115, Zeiss).

Fig. 9
MGL inhibition induces axonal growth

PCR

E16.5 embryonic brains (n = 4) were microdissected on ice to isolate cortical and thalamic regions and snap frozen in liquid N2 until processing. Primary cultures from cortex and thalamus were established at E16.5 and maintained for 4DIV at a density of 1 × 106 cells/well in PDL-coated 6 well plates (n = 2/region). RNA was extracted using the RNeasy mini kit (Qiagen) with a DNase I step performed to eliminate traces of genomic DNA (Supporting Fig. 4A1,A2) and reverse transcribed using a high-capacity cDNA reverse transcription kit (Applied Biosystems). Quantitative PCR reactions were performed after an initial 10-min 95°C hot start, 40 cycles of 95°C for 15s annealing at calculated temperatures followed by a dissociation stage (60/95°C for 10s each) and extension at 60°C for 60s (MyIQ, Bio-Rad) with primer pairs amplifying short fragments for each gene (Supplemental Fig. 4B). Samples without template or reverse transcriptase served as negative control. Expression levels were obtained by subtracting the value for each sample in the absence of reverse transcriptase from the corresponding value in the presence of reverse transcriptase and then normalizing to the housekeeping gene encoding GAPDH obtained for every sample in parallel assays (Berghuis et al., 2005).

Western blotting

Tissue samples were lysed in modified RIPA buffer containing 1 mM NaF, 1 mM Na3VO4, 0.1% N-octyl-β-D glucopyranoside, and a cocktail of protease inhibitors (Roche), denatured in 5× Laemmli buffer, and analyzed by SDS-PAGE (30 µg protein/sample) (Berghuis et al., 2005). Membranes were blocked in Odyssey blocking buffer (LiCor Biosciences; 1h) and exposed to primary antibodies (Supplemental Table 1) overnight at 4°C. β-III-tubulin (1:2,000; Promega) or β-actin (1:10,000; Promega) served as loading control. Appropriate combinations of IRDye800 and IRDye680 antibodies (LiCor Biosciences; from goat or rabbit hosts; 1:10,000, 2h) were used for signal detection on a LiCor Odyssey IR imager. Integrated optical densities were determined using ImageJ 1.32j. Experiments were performed in triplicate.

LC-MS/MS

2-AG concentrations were determined using an SPE LC-MS/MS method (Giuffrida et al., 2000). Tissues from n = 4–8 embryos/developmental stage were homogenized in ice-cold acetonitrile (containing [2H4]-AEA (6 pmols) as the internal standard), made up to 70% water and centrifuged at 13,000 rpm for 5 min. The supernatant was applied to Strata-X polymeric reversed phase cartridges (Phenomenex), methanol-eluted analytes were dried under N2, and the residue resuspended in mobile phase. A Surveyor LC system coupled to a TSQ Quantum mass spectrometer (Thermo Scientific) was used for analysis. The analytes were eluted from an ACE 5µ C8 column (150 × 2.1 mm; Hichrom Ltd) under isocratic conditions with a mobile phase consisting of 15% water, 85% methanol and 0.5% formic acid at a flow rate of 200 µl/min at 30°C. MS analysis was performed using electrospray ionisation in positive ion mode. Quantification was undertaken using single reaction monitoring of the parent ion–product ion transitions for 2-AG and [2H4]-AEA of m/z 379–m/z 287 and m/z 352.2–m/z 66.2, respectively. Two peaks were present in the chromatogram for 2-AG since a 1(3)-isomer exists in equilibrium with 2-AG. The areas of both peaks were combined to calculate [2-AG] by weighted linear regression analysis against suitable calibration standards using Xcalibur 2.0.6 software (Thermo Scientific). Results were expressed as nmol/g tissue.

Statistics

A p value of < 0.05 was considered statistically significant (Student’s t-test; SPSS v. 16.0 [SPSS Inc.]). Data were expressed as means ± sem. Fluorescence intensity distributions in individual axons were calculated by ImageJ1.32j and plotted in GraFit 5.0 (Erithacus Software).

Results

Developmental dynamics of MGL expression

CB1R and DAGL expression and function are tightly regulated to modulate neuronal polarization and axonal growth in the developing nervous system (Bisogno et al., 2003; Vitalis et al., 2008; Leterrier et al., 2006; Berghuis et al., 2007; Maison et al., 2009; Walker et al., 2010). Both pyramidal cells and interneurons rely on CB1Rs to transduce eCB signals (Berghuis et al., 2007; Mulder et al., 2008). DAGL expression and cell-autonomous activity are retained only by pyramidal cells, whereas GABAergic interneurons depend on extracellular 2-AG cues (Walker et al., 2010). In contrast, the spatiotemporal dynamics of MGL expression and function in the developing nervous system remain unknown.

We generated polyclonal antibodies raised against distinct MGL epitopes (Supplemental Table 1, Supplemental Fig. 3) to determine MGL’s distribution pattern in the developing nervous system of the mouse. We find MGL+ progenitors residing in the ventricular and subventricular zones (VZ/SVZ) of the telencephalic vesicles at E12.5 (Fig. 1A–A2). MGL+ pioneer axons are committed to the olfactory nerve (Fig. 1A1) and thalamic projections (Fig. 1A2) at this developmental stage. However, GFP+ GABAergic neurons migrating towards the cerebral cortex lack appreciable MGL expression (Fig. 1A1,A2).

Fig. 1
MGL localization in the developing nervous system

We used homozygous tau-EGFP mice to resolve MGL’s subcellular distribution in the developing mouse brain (Fig. 1B,B1) as well as peripheral ganglia and nerves at E14.5. Tau-EGFP mice were constructed by placing EGFP cDNA in-frame with the endogenous initiation codon of the tau gene such that a fusion protein is produced comprising the first 31 amino acids of tau followed by EGFP (Tucker et al., 2001). The chimeric protein is particularly advantageous in a developmental context since EGFP replaces the C-terminal microtubule-binding domains of tau, resulting in an entirely cytoplasmic EGFP signal in projection neurons, such as Brn-1+ cortical pyramidal cells (Fig. 1D3) (Sugitani et al., 2002), but not in GABA+ interneurons (data not shown).

Peripheral ganglia, including trigeminal (Fig. 1C) and dorsal root ganglia (data not shown), harboured many MGL+ neurons. Consequently, MGL+ axons concentrated in facial and mandibular trunks of the trigeminal nerve, including those innervating the whiskers, the spinal trigeminal tract (Fig. 1C1,C2), and the stalk of the optic nerve (Fig. 1C1). MGL+ central structures include the parabrachial/microcellular tegmental nucleus and the colliculi superior and inferior (Fig. 1C1,C3). In the forebrain, the olfactory nerve, VZ/SVZ progenitors, postmitotic cortical neurons and axons coursing along the palliosubpallial boundary, presumed thalamocortical axons (TCAs) were MGL+ (Fig. 1C,C1). By analyzing coronal sections of the fetal mouse brain we confirmed that both optic nerves and TCAs traversing the inferior thalamic radiation (Fig. 1D,D1) are MGL+. MGL+ TCAs advance in the subplate as far as the medial pallial fold (Fig. 1D2), and coexist with radially-migrating MGL+ postmitotic neurons exiting the SVZ - but not RC2+ radial glia -, and MGL/GFP+ GABA cells migrating tangentially in the marginal zone of this cortical domain. In the lateroventral isocortex, MGL+ ascending TCAs appear intermingled with radially-migrating Brn-1+/MGL+ cortical pyramidal cells and can target these cells once they reached the cortical plate (Fig. 1D4).

Most long-range forebrain tracts (Fig. 1E), including the peripheral (Fig. 1E1) and central segments (Fig. 1E2) of the optic nerve, lateral olfactory tract, fimbria hippocampi and TCAs, recruit MGL+ axons by E16.5, which we recognize as the developmental stage after which axonal MGL targeting terminates. After this time, MGL is restricted to the perisomatic segment and proximal dendrites both in the late-gestational brain (Fig. 1F) and at birth (data not shown). We find that restricted MGL expression inversely correlates with cortical and hippocampal 2-AG concentrations (Fig. 1G): 10.2 ± 1.1 (E14.5), 13.9 ± 3.2 (E16.5), 13.21 ± 1.8 (E18.5) ng/mg tissue vs. 21.2 ± 4.2 (P0), 35.78 ± 7.8 (P1; p < 0.05 vs. all fetal groups examined), 44.4 ± 9.8 ng/mg tissue (P2; p < 0.05 vs. all fetal groups examined). Collectively, our data suggest that MGL plays an essential role in determining 2-AG availability in the developing nervous system.

Regional differences in 2-AG synthesis and degradation in the corticothalamic axis

Previous studies support the notion that CB1Rs are primarily expressed in the developing neocortex (Berghuis et al., 2007; Morozov et al., 2009; Vitalis et al., 2008). Our present histochemical findings however place the primary site of MGL synthesis in the developing thalamus. We performed quantitative real-time PCR (qPCR) analysis to support spatial differences in 2-AG synthesis and degradation. In embryonic cortices and thalami isolated at E16.5 (n = 4) we have found that MGL mRNA levels (1.17 ± 0.07 [unscaled normalized values throughout]) significantly exceed those found in the cerebral cortex (0.85 ± 0.04) when normalized to GAPDH (p = 0.009; Fig. 2A). Similarly, DAGLβ mRNA expression was also significantly higher in the thalamus (1.09 ± 0.03) than in the cerebral cortex (0.81 ± 0.05; p = 0.003; Fig. 2B). Conspicuously, DAGLα coexists with DAGLβ at E16.5 (Fig. 2C) and exhibits similar regional variations (0.95 ± 0.02 [thalamus] vs. 0.055 ± 0.03 [cortex]; p < 0.001). In contrast, CB1R mRNA levels in the cerebral cortex exceed those in thalamus (0.88 ± 0.06 [thalamus] vs. 1.08 ± 0.05 [cortex]; p = 0.035; Fig. 2D).

Fig. 2
Foci of MGL expression and the developmental dynamics of 2-AG signaling

Next, we have performed qPCR analysis of primary cortical and thalamic neurons isolated at E16.5 and maintained for 4DIV to validate subsequent cell biology studies (Fig. 5Fig. 9) in cortical neurons endogenously expressing MGL, CB1R and DAGLs. We show that both neuron populations maintain their cellular specificities of expressing molecular components of the 2-AG signaling cassette (n = 2; Fig. 2A’-D’), as compared to data obtained in vivo (Fig. 2A–D).

Fig. 5
DAGLα and MGL expression in CB1R−/− telencephalon

To further dissect whether expression of metabolic and receptor components of the 2-AG signaling system at the protein level is temporally coordinated we analyzed pallial/cortical tissues (Fig. 2E–E3) and subpallial/striatal specimens (Supplemental Fig. 5) by Western blotting. We demonstrate that MGL’s 33 kDa isoform is selectively expressed in embryonic brain tissue (Fig. 2E). Comparative analysis of this isoform from E14.5 – P1 supports our histochemical findings by revealing transiently decreased MGL protein levels at around E.18.5 (E18.5: 0.49 ± 0.11 vs. P1 (cortex): 1.0 ± 0.00 (normalized); p = 0.010; Fig. 2E1,E2 and Supplemental Fig. 5A1,A2). In contrast, DAGLα expression peaks at E14.5/E16.5 with a dramatic decrease in DAGLα protein concentrations in neonates (E14.5: 14.41 ± 6.21 vs. P1 (hippocampus): 0.96 ± 0.34 (values were normalized to P1 cortical levels); p = 0.044; Fig. 2E1,E2 and Supplemental Fig. 5A1,A2). CB1R protein levels are largely unchanged throughout forebrain development (Fig. 2E1,E3 and Supplemental Fig. 5A1,A3).

CRIP1a can interact with the distal C-terminus of CB1R (Niehaus et al., 2007), and may attenuate CB1R-mediated inhibition of voltage-gated Ca2+ channels. However, CRIP1a’s developmental expression profile in relation to CB1Rs is unknown. We show that CRIP1a protein levels (Supplemental Fig. 1) are dynamically regulated in the developing nervous system with a progressive increase in cortical (E14.5: 0.57 ± 0.27 vs. P1 (hippocampus): 1.24 ± 0.28 (normalized to CRIP1a levels in P1 cortex), p = 0.005; Fig. 2E1,E3) and subpallial CRIP1a concentrations by birth (E14.5: 0.44 ± 0.07 vs. P1: 1.0 ± 0.00 (normalized); p = 0.040; Fig. Supplemental Fig. 5A1,A3). Overall, these experiments indicate that 2-AG metabolic enzymes and CB1R levels are controlled both at the mRNA and protein levels in vivo.

CB1Rs in growth cones of cortical pyramidal neurons

CB1Rs have hitherto been demonstrated to accumulate in growth cones of GABAergic interneurons (Berghuis et al., 2007) as well as in the shaft of corticofugal axons (CFAs) emanating from pyramidal cells (Berghuis et al., 2007; Vitalis et al., 2008). However, the presence of CB1Rs in motile growth cones of cortical pyramidal cells is ambiguous. We studied CB1R distribution at the ultrastructural level by correlated light- and electron microscopy. We find that CB1R+ axons are emitted earlier than previously thought (≤ E13; Fig. 3A). CB1Rs are distributed along the shafts and growth cones of CFAs that depart the cortical intermediate zone and transit the internal capsule (Fig. 3A,A1). CB1R+ axons navigate in the neuropil of the internal capsule separately from each other (Fig. 3A1). CB1Rs are transported in small vesicles along the axon (Fig. 3B), and concentrate in motile filopodia that protrude at random from individual growth cones (Fig. 3C,C1). Pathfinding decisions by CB1R+ growth cones do not rely on the alignment of CB1R+ axons with each other as we detected using electron microscopy with three-dimensional reconstruction (Fig. 3A2,C,C1). Thus, CB1R expression during CFA tract formation is poised to allow eCBs to influence both the elongation and growth cone steering decisions of excitatory cortical efferents.

Fig. 3
CB1Rs in corticofugal afferents

Our present and previous (Berghuis et al., 2007; Mulder et al., 2008) findings suggest that CB1Rs are selectively expressed by cortical neurons – including pyramidal cells – and can affect the elongation and guidance of CFAs. We tested this notion by electroporating cortical pyramidal cells and thalamic projection neurons with an EGFP vector in utero. Our data demonstrate that CB1Rs are present in CFAs coursing deep in the intermediate zone (IZ; Fig. 3D1-d3) but absent from superficial TCAs (Fig. 3E1-e3). By using high-resolution laser-scanning microscopy we clearly show co-localization of pyramidal cell-derived EGFP and CB1R signals (Fig. 3d1’-d3) whilst revealing a mutually exclusive distribution pattern of CB1Rs and EGFP expressed by thalamic neurons (Fig. 3e1’-e3). Overall, our results define the axonal specificity of CB1Rs during corticogenesis.

MGL and CB1Rs are coexpressed in corticofugal but not thalamocortical axons

The presence of MGL mRNA in the cerebral cortex suggests that MGL expression persists in developing cortical neurons. We examined MGL expression by cortical pyramidal cells by analyzing whether MGL co-localizes with CB1Rs (Fig. 4A) that we have characterized as a specific pallial marker (Fig. 3D3). High-resolution microscopy revealed that pyramidal cells populating the cortical plate at E16.5 harbour both MGL and CB1R immunoreactivities (Fig. 4A1). Accordingly, MGL+/CB1R+ axons populated the IZ of the cerebral cortex (Fig. 4A2). We observed that MGL+ axons are more numerous in the IZ than those containing CB1Rs (area occupancy (% of region of interest): 31.7 ± 3.0% (CB1R+) vs. 68.4 ± 3.0% (MGL+); Fig. 4C) with 6.7 ± 1.3% of MGL+ axons also containing CB1Rs. Conversely, 13.1 ± 2.0% of CB1R+ axonal profiles harboured MGL immunoreactivity (Fig. 4C1).

Fig. 4
Differential co-localization of CB1Rs and MGL in the cerebral cortex and thalamus

In the thalamus, however, MGL+ axonal profiles were far more frequently encountered than CB1R+ profiles (area occupancy (% of region of interest): 94.7 ± 2.0% (MGL+) vs. 5.3 ± 2.0% (CB1R+); Fig. 4B–B1”,C). Only 1.0 ± 0.1% of MGL+ axons contained CB1Rs, while 17.9 ± 4.8% of CB1R-containing axonal profiles were dual labelled (Fig. 4C1). The Pearson correlation coefficient of dual labelled structures did not differ from R = 0, suggesting a lack of a direct relationship (co-regulation) of CB1R and MGL levels in individual axonal profiles (Fig. 4C2).

We found that MGL+ and CB1R+ axons are spatially segregated in the fimbria hippocampi (Fig. 4D). In fact, the fimbria can be subdivided into ventrolateral/CB1R+, median/mixed and dorsomedial/MGL+ domains in coronal sections (Fig. 4D1-D3). We have confirmed this notion by quantitative morphometry showing inverse MGL/CB1R co-localization probabilities in these domains (Fig. 4D4). Together, these findings suggest that CB1Rs can co-exist with MGL in CFAs. In contrast, the overwhelming majority of TCAs only contain MGL (Fig. 4E). Therefore, we suggest that TCAs can function as 2-AG-inactivating barriers to shape forward-facing 2-AG gradients, to minimize 2-AG ‘spill-over’, and to promote CFA pathfinding.

CB1Rs are indispensable for axon fasciculation but dispensable for DAGLα or MGL expression and axonal targeting

The physiological outcome of eCB signaling is determined hierarchically by CB1Rs being available at the cell-surface (Hsieh et al., 1999), their differential recruitment of signal transduction pathways (Derkinderen et al., 2003) as well as the momentary metabolic balance between 2-AG synthesis (DAGL) and degrading (MGL) activities. Our present and previous data (Mulder et al., 2008) together establish that MGL is co-expressed and co-targeted with CB1Rs and DAGLs in CFAs at mid-gestation. The coincident presence of enzymatic and receptor components of 2-AG signaling in CFAs allows us to address whether DAGLα and MGL expression and axonal targeting in fasciculating CFAs are linked to CB1Rs. We tested this possibility in E16.5 CB1R−/− mice that exhibit enlarged CFA fascicles relative to their age-matched wild-type littermates (Mulder et al., 2008). We validated that CB1R activity in CFAs is indispensable for appropriately timed axonal elongation and fasciculation to occur as enlarged CFA fascicles can be seen in CB1R−/− mice when localizing both DAGLα and MGL (Fig. 5).

Next, we have explored whether the CB1R itself and/or the redundancy of signaling-competent 2-AG in the absence of its cognate receptor can affect DAGLα or MGL expression and CFA targeting. Neither DAGLα (Fig. 5B–B1) nor MGL expression (Fig. 5C–C1) in cortical territories is dependent on CB1Rs. In fact, the bundled CFA phenotype in CB1R−/− mice amplifies the presence of both enzymes otherwise sparsely distributed in axons with parallel trajectories in wild-type cortices (Fig. 5B1’,C1). Although we cannot exclude subtle alterations to the temporal control of DAGL and/or MGL expression or degradation in the absence of CB1Rs, our findings suggest that CB1R does not exert significant upstream control of DAGL and MGL expression at mid-gestation.

Mutually exclusive subcellular distribution of DAGLα and MGL in developing axons

Any guidance cue or elongation factor requires a discrete subcellular niche, particularly the growth cone, where temporally and spatially restricted ligand-receptor interactions can occur and translate into a growth response. eCB signaling has unique properties as this ligand family is lipophilic and can diffuse in biological membranes over significant distances (Chevaleyre et al., 2006) and exert their action, at least in part, through cell-autonomous mechanisms (Mulder et al., 2008). We hypothesized therefore that 2-AG synthesis by DAGLα/DAGLβ (Mulder et al., 2008) must exceed MGL-dependent 2-AG degradation in axonal growth cones to generate 2-AG-rich hotspots for directional axonal growth. Individual axons developing in vitro provide a suitable model to assess this hypothesis by allowing precise, correlated localization of DAGLs and MGL as they elongate. Maturation of cortical neurons is not only characterized by the spatial expansion of their axons but also by the appearance of varicose structures (Dotti et al., 1988) with each varicosity recognized as a functionally active signaling entity.

In cortical cultures with elaborate yet immature axonal meshworks (4DIV), DAGLα and MGL co-exist in presynaptic varicosities (Fig. 6A,A1). However, DAGLα is reduced in presynapse-like varicosities (Fig. 6B) once synaptogenesis concludes (Mulder et al., 2008). In contrast, MGL retains its presynaptic localization both within fasciculating axons (Fig. 6C) and VAMP2 (synaptobrevin 2)+ presynapses, whether autaptic or heterotaptic (Fig. 6D,D1), thus recapitulating MGL’s distribution in adult brain (Dinh et al., 2002; Gulyas et al., 2004).

Fig. 6
Differential subcellular targeting of DAGLα and MGL during axon development

Subcellular analysis revealed that MGL accumulates in tubulin+ consolidating axon shafts with its levels tailing off towards the actin-rich motile axon tip leaving a ‘barrier region’ of 9–12 µm with low MGL levels (termed ‘MGL delay’ throughout; Fig. 6E–E3). To gain insights into the temporal dynamics of axonal MGL accumulation, we have compared MGL’s distribution at successive stages of axon development (Dotti et al., 1988). MGL is preferentially targeted to the quiescent axon once neuronal polarization occurs (Fig. 6E). Elongating axons retain MGL in their stable proximal segments (Fig. 6E1) with a surprisingly steep decrement of MGL towards their actin+ distal tip (Fig. 6E1,E1). Compartmentalized MGL distribution is a fundamental hallmark of axon development and is independent of the morphology – whether bundled, spread or looped (Morii et al., 2006) – of co-existing growth cones (Fig. 6E2-E3). Notably, subcellular DAGLα and MGL localization is significantly different in motile growth cones with DAGLα but not MGL being present (Fig. 6F,G). In conclusion, DAGLα and MGL exhibit mutually exclusive distribution in motile neurites, where MGL’s exclusion from the growth cone defines a subcellular niche for protrusive 2-AG signaling.

Proteasomal degradation is a candidate mechanism to exclude MGL from growth cones

The ubiquitin proteasome system (UPS) has been implicated in defining dynamic structural rearrangements during axonal growth (Haas and Broadie, 2008). Preferential UPS-mediated degradation of cytoskeletal and signalosome complexes underscores the continuous structural reorganization within the growth cone during its steering decisions (Campbell and Holt, 2001). The restricted localization of MGL to the immobile axon shaft led us to hypothesize that MGL degradation in the motile neurite tip could maintain the growth cone’s sensitivity to 2-AG. Bioinformatic tools (http://elm.eu.org) predict a destruction box motif (D-box) in MGL suggesting that MGL could be degraded by the 20S proteasome within the motile axon ending. We have experimentally tested whether compartmentalized proteasomal degradation contributes to MGL’s axonal gradient by exposing cortical neurons to lactacystin (20 µM) to inactivate the catalytic site of the 20S proteasome (Omura et al., 1991). Since UPS inhibition affects the turnover of many proteins essential for neuronal survival or differentiation, we have established in vitro conditions where UPS inhibition does not compromise cell viability (Fig. 7E) but affects MGL turnover (Fig. 7A–C). We find that UPS inhibition disrupts MGL distribution such that MGL becomes indiscriminately present in the axon and dendrites (Fig. 7B,C) and ventures into growth cones (Fig. 7C2,C3). Fluorescence intensity distribution analysis of MGL+ axons revealed that UPS inhibition dissipates the spatial segregation of MGL+ (established) and actin+ (motile) axon segments (Fig. 7D,E5). Ectopic MGL accumulation is observed in dendrites upon lactacystin-induced disruption of MGL turnover (Fig. 7C,F-H1).

Fig. 7
Proteasomal degradation excludes MGL from the motile neurite segment

If 2-AG hydrolysis by MGL impedes axonal growth then disrupting MGL’s subcellular distribution will shorten axon length. Although an impaired UPS can increase the bioavailability of many proteins pivotal for axonal growth and thus disturb combinatorial signaling in growth cones, we argued that our model allows testing the premise that a molecular link between MGL stabilization in axons and discordant neurite outgrowth can exist. We find that UPS inhibition reduces the length of the lead neurite (Fig. 7E1) and prunes both axon collateral complexity (Fig. 7B,C,E2) and dendritogenesis (Fig. 7H) of cortical neurons. These findings suggest that MGL turnover is differentially regulated in the motile and consolidated axon segments and can affect axonal elongation.

Synaptogenesis disrupts the axonal MGL microgradient

While MGL largely avoids the motile neurite segment, it accumulates in presynapses of cultured neurons (Fig. 8) as well as many presynaptic terminals of the adult cerebral cortex (Dinh et al., 2002; Kano et al., 2009; Gulyas et al., 2004). This presents the possibility that MGL redistribution in the growth cone is physiologically relevant to decrease the velocity of 2-AG-induced motility when a growth cone approaches its postsynaptic target. Therefore, we have determined if subcellular MGL distribution changes during synaptogenesis. We find that MGL accumulates in growth cones that appose a postsynaptic neuron in vitro (Fig. 8A–B3, Supplemental Fig. 6A,D-D2). In contrast, growth cones of axon collaterals who have not selected a target remain MGL (Fig. 8A, Supplemental Fig. 6A–C2). These data suggest that MGL’s axonal polarity dissipates and MGL can limit 2-AG signaling as a growth cone engages in its postsynaptic target selection (Fig. 8C,C1).

Fig. 8
Synaptogenesis coincides with subcellular MGL redistribution

MGL inhibition induces axonal growth

Although evidence is accumulating that CB1Rs affects (in isolation or synergistically with other receptors) axonal growth and steering decisions, evidence on the molecular identity of the eCB required for axonal growth is still lacking. Our findings could imply that 2-AG may function as an axonal elongation signal. We tested this possibility by inhibiting MGL’s enzymatic activity with JZL184 (100 nM), a selective MGL inhibitor (Long et al., 2009). Exposure to JZL184 (16h) invariably triggers neurite outgrowth both in cells that emit a stunted quiescent axon shortly after plating (Fig. 9A–B2) and in neurons with an established primary neurite in vitro (Fig. 9C–C2). We have confirmed these data by applying URB 602 (5 µM), an alternative MGL inhibitor (King et al., 2007), whose application also increases axonal growth (data not shown). Notably, MGL inhibition regulates neither the length of the actin+ distal neurite segment (Fig. 9B2,C2) nor compartmentalized MGL distribution (Fig. 9B3,C3) in axons, thus suggesting that MGL inactivation does not directly influence MGL degradation.

Overall, our data suggest that MGL exerts dual functions during axonal growth: MGL may form an intracellular barrier keeping lipophilic 2-AG from diffusing retrogradely from the growth cone in the axonal plasma membrane to prematurely engage CB1Rs and induce ectopic growth responses (Fig. 8C,C1). In addition, the exclusion of MGL from the motile neurite tip could allow for cell-autonomous or target-derived 2-AG to selectively impact the growth cone and trigger axonal elongation in a coordinated fashion.

2-AG is one of the many potential targets of MGL in vivo (Nomura et al., 2010). It is therefore possible that MGL hydrolyses a ligand distinct from 2-AG to regulate axonal elongation. To exclude this possibility, we treated neurons with JZL184 in combination with O-3841 or THL, DAGL inhibitors. We show that coincident blockade of MGL and DAGL activities by JZL184 and either O-3841 (104.2 ± 6.7 µm (JZL184, n = 39) vs. 80.4 ± 4.9 µm (JZL184 + O-3841, n = 40); p = 0.005; Fig. 9D–D2,F1) or THL (104.2 ± 6.7 µm (JZL184, n = 39) vs. 64.5 ± 4.3 µm (JZL184 + THL, n = 32); p < 0.001) abolishes the JZL184-induced growth response. We verified that 2-AG’s effect is mediated by CB1Rs by showing that O-2050, a neutral CB1R antagonist, significantly attenuates JZL184-induced neurite extension (104.2 ± 6.7 µm (JZL184, n = 39) vs. 84.3 ± 6.6 µm (JZL184 + O-2050, n = 35); p = 0.036; Fig. 9D1 vs. 9D3, 9F1). Neuronal morphology was not compromised by any of the drugs used, as reflected by an unchanged number of processes (Fig. 9F2).

Endocannabinoids have been shown to induce repulsive growth cone turning by activating RhoA GTPases (Berghuis et al., 2007). A repulsive response of motile growth cones will invariably couple to axonal elongation since directional growth is required to avoid the chemorepulsive cue. This phenomenon can also exist when ligands are indiscriminately present in culture media, as in our model, with the outcome being structural rearrangements within the growth cone and chaotic axonal elongation. Therefore, determining the growth cone size will reveal whether surplus 2-AG impacts growth cone morphology in neurons deficient in MGL activity. Growth cones of cortical pyramidal cells retained chaotic filopodial complexity in vitro (Fig. 2C, Fig. 9E1) and in vivo (Fig. 3C). JZL184 induced a growth cone phenotype reminiscent of immature motile neurite tips (surface size: 8.57 ± 1.16 µm2 (JZL184, n = 24) vs. 15.78 ± 1.55 µm2 (control, n = 33), p < 0.001; Fig. 9G) possessing a lead filopodium (Fig. 1E2). O-3841 (surface size: 15.92 ± 2.00 µm2 (n = 25), p = 0.003 vs. JZL184; Fig. 9E3,G) but not THL (p = 0.738 vs. JZL184; Fig. 9G) significantly reduced JZL184-induced growth cone remodelling. Similarly, CB1R blockade by O-2050 markedly impeded the JZL184-induced reduction of growth cone size (surface size: 12.36 ± 1.81 µm2 (n = 26), p = 0.085 vs. JZL184; Fig. 9G). In sum, our data reconcile that 2-AG can act as both a directional cue (Berghuis et al., 2007) and an elongation factor whilst sculpting axonal complexity.

Discussion

MGL in the developing nervous system

The prevailing view that eCBs, particularly 2-AG, exert many functions in the developing nervous system is underscored by a rapidly expanding cohort of experimental studies demonstrating eCB-dependent neural progenitor self-renewal and neurogenic commitment (Goncalves et al., 2008; Aguado et al., 2006; Aguado et al., 2005), long-range as well as local neuronal migration (Morozov et al., 2009; Mulder et al., 2008), and synaptogenesis (Berghuis et al., 2007). eCB signaling is likely to coexist and cooperate with signaling cascades indispensable for neuronal identification, including neurotrophins (Maison et al., 2009) and chemokines (Zorina et al., 2010). Compelling evidence indicates that both DAGL-dependent 2-AG synthesis and CB1R-dependent signal transduction are under cell-state-specific regulatory control of BDNF (Maison et al., 2009) and FGF receptor signaling cascades (Williams et al., 2003). It is not surprising therefore that eCB actions underpinning neuronal diversification and axonal growth are precisely timed and spatially coordinated in the developing brain (Bisogno et al., 2003). The precision of 2-AG signaling in a neurodevelopmental context is emphasized by DAGLs’ translocation from axonal tracts once synaptogenesis concludes (Bisogno et al., 2003) to dendritic spines apposing mature presynapses to maintain retrograde signaling (Katona et al., 2006; Yoshida et al., 2006). 2-AG degradation by MGL, and probably also by ABHD6 and ABHD12 lipases (Blankman et al., 2007; Straiker et al., 2009; Hashimotodani et al., 2007), is critical to maintain the temporal dynamics of retrograde synaptic communication and the sensitivity of presynaptic CB1Rs to activity-dependent transient peaks of extracellular 2-AG concentrations. It is therefore physiologically necessary to place MGL into the presynapse (Gulyas et al., 2004) where it can rapidly terminate 2-AG signaling (Hashimotodani et al., 2007).

Dynamic subcellular recruitment of both metabolic and receptor components of 2-AG signaling networks in the developing nervous system is achieved through cell-autonomous programming of both the expression and subcellular sorting of DAGLs, MGL and CB1Rs. We find that MGL is coincidently expressed with CB1Rs and DAGLs by E12 in mouse, thus providing critical hydrolytic activity to terminate undesired 2-AG actions when the telencephalic SVZ progenitor pool begins to expand. MGL’s differential recruitment to distinct subcellular domains of neurons, particularly the consolidated axon shaft, provides an appealing candidate for the cell-autonomous regulation of 2-AG-dependent positional activation of CB1Rs. In fact, neurons can spatially confine their 2-AG-inactivating enzymatic capacity intracellularly such that CB1Rs are kept inactive whilst undergoing vesicular transport along the axon even in the presence of membrane-diffusible 2-AG. Since agonist activation of CB1Rs can result in surplus neurite branching in vitro (Mulder et al., 2008), the molecular arrangements we uncovered suggest that MGL activity in the immotile axon shaft is required and sufficient to prevent discordant signaling events that could manifest in ectopic branching and axon guidance errors.

Transient removal of MGL from axonal tracts during the perinatal period (E18.5-P2) may have intriguing physiological implications. MGL’s arrest in neuronal perikarya and dendrites coincides with a previously reported, yet unexplained, peak (up to ~9 ng/g tissue) in perinatal tissue 2-AG levels (Berrendero et al., 1999). Our analysis significantly extends these observations by showing that 2-AG levels are increased due to a transient lack of 2-AG hydrolysis capacity in the neonatal hippocampus (up to ~45 ng/g tissue) with minor changes in other brain regions. We suggest that the neonatal 2-AG peak in the hippocampus can provide a mechanism to mute synaptic information processing, thus preventing memory formation during delivery.

An ~1,000-fold excess of tissue 2-AG concentrations over those of anandamide (AEA) exists in the fetal brain (Berrendero et al., 1999). This observation together with our detailed understanding of the metabolic network controlling 2-AG bioavailability (Bisogno et al., 2003; Nomura et al., 2010) prompted the molecular dissection of neurodevelopmental 2-AG signaling. Nevertheless, in vitro data (Berghuis et al., 2005; Mulder et al., 2008; Aguado et al., 2005) convincingly demonstrate that AEA can also elicit physiologically-relevant CB1R-mediated responses in developing neurons. AEA may also be involved in fine-tuning 2-AG bioavailability (Maccarrone et al., 2008). Hence, we expect future studies to unravel AEA-specific signaling events and add an additional level of signaling complexity when alternative eCBs are present, with eCBs conferring specific modalities to neuronal subclass diversification during nervous system induction.

Positional ligand inactivation confers spatial specificity in 2-AG signaling

Our quantitative morphometry demonstrates that MGL can coexist with both CB1Rs and DAGL to promote cell-autonomous axonal growth of neocortical pyramidal cells. In contrast, CB1Rs are absent from MGL+ TCAs. We attribute the scarce co-existence of MGL+/CB1R+ axonal profiles in thalamic territories to CTAs invading particular nuclei. The remarkable neurochemical dichotomy of CFAs and TCAs in the context of 2-AG signaling led us to propose novel roles for 2-AG signaling during the ‘handshake’ of these axons. The ‘handshake’ hypothesis implies that axons from the thalamus and from early-born cortical preplate cells meet and intermingle in the basal telencephalon whereafter thalamic axons use the scaffold of CFAs to enter the cortical plate (Molnar and Blakemore, 1995). Our findings provide an additional facet of information to this hypothesis by identifying MGL-mediated 2-AG inactivation in TCAs as a mechanism to limit unwanted 2-AG ‘spill-over’ likely masking steep local ligand microgradients, and to refine the extracellular 2-AG microgradient map and to determine CB1R-dependent directional CFA growth (Fig. 4E). 2-AG’s ability to act as an extracellular guidance signal is suggested by impaired retrograde signaling in DAGL−/− mice (Gao et al., 2010; Tanimura et al., 2010), demonstrating that 2-AG can be liberated from specific neuronal compartments to engage presynaptic CB1Rs after commuting in the extracellular matrix.

Reconciling eCB-induced chemorepulsion and axonal growth

Since CB1R activation powerfully induces cytoskeletal rearrangements (Ishii and Chun, 2002), focal 2-AG catabolism is critical to isolate cellular microdomains in which 2-AG-induced activation of CB1Rs will evoke a specific growth response. CB1R activation in axonal growth cones of cortical neurons has previously been shown to induce chemorepulsive steering decisions when presenting an extracellular ligand microgradient (Berghuis et al., 2007). Since both attractive and repulsive extracellular guidance cues must elicit cytoskeletal re-mobilization of the distal (motile) axon segment to facilitate axonal elongation (either towards or away from the source of the guidance molecule), CB1R-dependent repulsive growth cone turning ultimately relies on the directional extension of the motile axon segment (Berghuis et al., 2007) with RhoA GTPases triggering cytoskeletal remodelling in the navigating growth cone.

Exposing neurons to homogenously distributed ligands, such as the bath applied enzyme inhibitors or CB1R agonists used here, will evoke neurite outgrowth. However, bath application will eliminate a chemotropic ligand’s ability to evoke directional growth responses. Instead, axonal trajectories will be chaotic in the absence of discrete synthesis and release sites. Therefore, the experimental paradigm we used will only allow us to study whether 2-AG can promote axonal growth per se. Since MGL inhibition by JZL184 couples to an axonal growth response we conclude that 2-AG clearly possesses such a capacity when engaging CB1Rs in growth cones. It is noteworthy that JZL184-treated neurons exhibit axonal growth cone morphologies reminiscent to those seen after gradient CB1R activation (Berghuis et al., 2007): a clear reduction in the number of filopodia as well as in the surface size of growth cones argues that massive growth cone remodelling occurs when 2-AG levels become elevated. Our finding that O-3841 but not THL reinstate the size and filopodial complexity of axonal growth cones hints that these antagonists may differentially affect DAGLα or DAGLβ, can have different efficacies to block 2-AG synthesis or off-target effects (e.g., THL can inhibit ABHD12 (Hoover et al., 2008)) in developing neurons.

Overall, our data strongly suggest that 2-AG signaling exerts dual roles in developing neurons by impacting both growth cone navigation and axonal elongation. In this regard, MGL’s refined proteasomal regulation might not only contribute to the maintenance of axonal 2-AG microgradients but can also rapidly reconfigure MGL distribution to occlude protrusive 2-AG signaling. Such a mechanism can be particularly powerful to act as a halting signal to prevent aberrant elongation of an axon beyond its physiologically appropriate postsynaptic target. Notably, MGL stabilization (‘overexpression’) and inhibition inversely modulate 2-AG availability, which translates into a differential axon growth response irrespective of the stage of axon development. The magnitude of axonal growth we observed cannot be augmented by prolonged MGL inhibition suggesting CB1R desensitization or accelerated receptor recycling and removal (Hsieh et al., 1999) once 2-AG levels reach a critical supraphysiological threshold.

MGL is generally viewed to degrade 2-AG in the brain. However, Nomura et al. (2010) have recently reported that MGL can degrade a broad variety of bioactive monoacylglycerols. Therefore, we suggest that the developmentally defined composition of MGL’s substrate pool will determine its metabolic significance. Our experiments cumulatively suggest that MGL’s primary target to modulate axonal growth and guidance is an endogenous CB1R agonist synthesized by DAGLs. Although we cannot entirely exclude the contribution of alternative monoacylglycerols to developmental processes, the above molecular characteristics together with an in vivo inverse relationship between neonatal MGL expression and tissue 2-AG concentrations suggest that 2-AG can be a physiologically relevant candidate to mediate axonal growth responses. Assuming that subcellular accumulation of DAGLs and MGL directly reflect their increased focal enzymatic activity we conclude that MGL’s developmental role is to sculpt the spatial dynamics of 2-AG-rich hotspots allowing 2-AG to function as a local protrusive signal facilitating neurite elongation. Thus, the spatiotemporal control of 2-AG metabolism is a key determinant of eCB signaling during establishment of the wiring diagram in cortical neuronal networks, and modifications to the subcellular control of eCB actions may be intrinsic to the pathogenesis of congenital disorders associated with aberrant telencephalic axon patterning.

Supplementary Material

Supp1

Acknowledgments

The authors thank C. Ledent and Y.A. Barde for colony founders of CB1R−/− and tau-EGFP mice, respectively. Y. Zilberter, H.-C. Lu, R. Iyengar, R.A. Ross and P. Doherty are acknowledged for their constructive criticism. We thank R. Hessling and J. Lindenau (Zeiss) for expert advice and assistance with quantitative immunofluorescence analysis. This work was supported by the Scottish Universities Life Science Alliance (SULSA; TH), European Molecular Biology Organization Young Investigator Programme (TH), Swedish Medical Research Council (TH), Alzheimer’s Research Trust UK (TH), Alzheimer’s Association (KM, TH), European Commission (HEALTH-F2-2007-201159, TH), Grant-in-Aid for Scientific Research from the MEXT, Japan (YY), Takeda Science Foundation (YY), the March of Dimes Birth Defects Foundation (YMM), the Kavli Institute for Neuroscience at Yale (YMM), and National Institutes of Health grants (DA023214 (TH), DA11322 (KM), and DA21696 (KM)).

Reference List

  • Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzman M, Galve-Roperh I. The endocannabinoid system drives neural progenitor proliferation. FASEB J. 2005;19:1704–1706. [PubMed]
  • Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzman M, Galve-Roperh I. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci. 2006;26:1551–1561. [PubMed]
  • Begbie J, Doherty P, Graham A. Cannabinoid receptor, CB1, expression follows neuronal differentiation in the early chick embryo. J Anat. 2004;205:213–218. [PMC free article] [PubMed]
  • Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, Hurd YL, Harkany T. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A. 2005;102:19115–19120. [PMC free article] [PubMed]
  • Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316:1212–1216. [PubMed]
  • Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse. 1999;33:181–191. [PubMed]
  • Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, Saturnino C, Martin B, Razdan R, Di Marzo V. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta. 2006;1761:205–212. [PubMed]
  • Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463–468. [PMC free article] [PubMed]
  • Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007;14:1347–1356. [PMC free article] [PubMed]
  • Bromberg KD, Ma’ayan A, Neves SR, Iyengar R. Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science. 2008;320:903–909. [PMC free article] [PubMed]
  • Campbell DS, Holt CE. Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron. 2001;32:1013–1026. [PubMed]
  • Chevaleyre V, Takahashi KA, Castillo PE. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci. 2006;29:37–76. [PubMed]
  • Coutts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K, Pertwee RG, Irving AJ. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci. 2001;21:2425–2433. [PubMed]
  • Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci. 2003;23:2371–2382. [PubMed]
  • Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99:10819–10824. [PMC free article] [PubMed]
  • Dotti CG, Sullivan CA, Banker GA. The establishment of polarity by hippocampal neurons in culture. J Neurosci. 1988;8:1454–1468. [PubMed]
  • Fishell G, Hanashima C. Pyramidal neurons grow up and change their mind. Neuron. 2008;57:333–338. [PubMed]
  • Gao Y, et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci. 2010;30:2017–2024. [PubMed]
  • Giuffrida A, Rodriguez de FF, Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem. 2000;280:87–93. [PubMed]
  • Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ, Zentar MP, Pollard S, Yanez-Munoz RJ, Williams G, Walsh FS, Pangalos MN, Doherty P. A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci. 2008 in press. [PubMed]
  • Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, Freund TF. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20:441–458. [PubMed]
  • Haas KF, Broadie K. Roles of ubiquitination at the synapse. Biochim Biophys Acta. 2008;1779:495–506. [PMC free article] [PubMed]
  • Hashimotodani Y, Ohno-Shosaku T, Kano M. Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus. J Neurosci. 2007;27:1211–1219. [PubMed]
  • Hoover HS, Blankman JL, Niessen S, Cravatt BF. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett. 2008;18:5838–5841. [PMC free article] [PubMed]
  • Hsieh C, Brown S, Derleth C, Mackie K. Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem. 1999;73:493–501. [PubMed]
  • Ibanez CF, Ernfors P. Hierarchical control of sensory neuron development by neurotrophic factors. Neuron. 2007;54:673–675. [PubMed]
  • Ishii I, Chun J. Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. Neuroreport. 2002;13:593–596. [PubMed]
  • Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309–380. [PubMed]
  • Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D, Mackie K, Freund TF. Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci. 2006;26:5628–5637. [PMC free article] [PubMed]
  • King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper JR, Astarita G, Geaga JA, Luecke H, Mor M, Tarzia G, Piomelli D. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol. 2007;14:1357–1365. [PMC free article] [PubMed]
  • Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401–404. [PubMed]
  • Leterrier C, Laine J, Darmon M, Boudin H, Rossier J, Lenkei Z. Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J Neurosci. 2006;26:3141–3153. [PubMed]
  • Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009;5:37–44. [PMC free article] [PubMed]
  • Maccarrone M, Rossi S, Bari M, De CV, Fezza F, Musella A, Gasperi V, Prosperetti C, Bernardi G, Finazzi-Agro A, Cravatt BF, Centonze D. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci. 2008;11:152–159. [PubMed]
  • Maison P, Walker DJ, Walsh FS, Williams G, Doherty P. BDNF regulates neuronal sensitivity to endocannabinoids. Neurosci Lett. 2009;467:90–94. [PubMed]
  • Molnar Z, Blakemore C. How do thalamic axons find their way to the cortex? Trends Neurosci. 1995;18:389–397. [PubMed]
  • Morii H, Shiraishi-Yamaguchi Y, Mori N. SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons. J Neurobiol. 2006;66:1101–1114. [PubMed]
  • Morozov YM, Torii M, Rakic P. Origin, early commitment, migratory routes, and destination of cannabinoid type 1 receptor-containing interneurons. Cereb Cortex. 2009;19 Suppl 1:i78–i89. [PMC free article] [PubMed]
  • Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, Monory K, Marsicano G, Di Marzo V, Hurd YL, Guillemot F, Mackie K, Lutz B, Guzman M, Lu HC, Galve-Roperh I, Harkany T. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A. 2008;105:8760–8765. [PMC free article] [PubMed]
  • Mulder J, Zilberter M, Spence L, Tortoriello G, Uhlen M, Yanagawa Y, Aujard F, Hokfelt T, Harkany T. Secretagogin is a Ca2+-binding protein specifying subpopulations of telencephalic neurons. Proc Natl Acad Sci U S A. 2009;106:22492–22497. [PMC free article] [PubMed]
  • Niehaus JL, Liu Y, Wallis KT, Egertova M, Bhartur SG, Mukhopadhyay S, Shi S, He H, Selley DE, Howlett AC, Elphick MR, Lewis DL. CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol Pharmacol. 2007;72:1557–1566. [PubMed]
  • Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140:49–61. [PMC free article] [PubMed]
  • Omura S, Matsuzaki K, Fujimoto T, Kosuge K, Furuya T, Fujita S, Nakagawa A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot (Tokyo) 1991;44:117–118. [PubMed]
  • Straiker A, Hu SS, Long J, Arnold A, Wager-Miller J, Cravatt BF, Mackie K. Monoacyl glycerol lipase (MGL) limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation (DSE) in autaptic hippocampal neurons. Mol Pharmacol. 2009 [PMC free article] [PubMed]
  • Sugitani Y, Nakai S, Minowa O, Nishi M, Jishage K, Kawano H, Mori K, Ogawa M, Noda T. Brn-1 and Brn-2 share crucial roles in the production and positioning of mouse neocortical neurons. Genes Dev. 2002;16:1760–1765. [PMC free article] [PubMed]
  • Tamamaki N, Yanagawa Y, Tomioka R, Miyazaki J, Obata K, Kaneko T. Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse. J Comp Neurol. 2003;467:60–79. [PubMed]
  • Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, Kita Y, Hashimoto K, Shimizu T, Watanabe M, Sakimura K, Kano M. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron. 2010;65:320–327. [PubMed]
  • Torii M, Hashimoto-Torii K, Levitt P, Rakic P. Integration of neuronal clones in the radial cortical columns by EphA and ephrin-A signalling. Nature. 2009;461:524–528. [PMC free article] [PubMed]
  • Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4:29–37. [PubMed]
  • Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 1997;78:43–50. [PubMed]
  • Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci. 2007;27:3663–3676. [PubMed]
  • Vitalis T, Laine J, Simon A, Roland A, Leterrier C, Lenkei Z. The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurons and negatively regulates neurite growth in vitro. Eur J Neurosci. 2008;28:1705–1718. [PubMed]
  • Walker DJ, Suetterlin P, Reisenberg M, Williams G, Doherty P. Down-regulation of diacylglycerol lipase-alpha during neural stem cell differentiation: Identification of elements that regulate transcription. J Neurosci Res. 2010;88:735–745. [PubMed]
  • Watson S, Chambers D, Hobbs C, Doherty P, Graham A. The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation. Mol Cell Neurosci. 2008;38:89–97. [PubMed]
  • Williams EJ, Walsh FS, Doherty P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol. 2003;160:481–486. [PMC free article] [PubMed]
  • Xiang Y, Li Y, Zhang Z, Cui K, Wang S, Yuan XB, Wu CP, Poo MM, Duan S. Nerve growth cone guidance mediated by G protein-coupled receptors. Nat Neurosci. 2002;5:843–848. [PubMed]
  • Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, Watanabe M. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci. 2006;26:4740–4751. [PubMed]
  • Zorina Y, Iyengar R, Bromberg KD. Cannabinoid 1 receptor and interleukin-6 receptor together induce integration of protein kinase and transcription factor signaling to trigger neurite outgrowth. J Biol Chem. 2010;285:1358–1370. [PMC free article] [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • Gene
    Gene
    Gene links
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence links
  • GEO Profiles
    GEO Profiles
    Related GEO records
  • HomoloGene
    HomoloGene
    HomoloGene links
  • MedGen
    MedGen
    Related information in MedGen
  • Nucleotide
    Nucleotide
    Published Nucleotide sequences
  • Pathways + GO
    Pathways + GO
    Pathways, annotations and biological systems (BioSystems) that cite the current article.
  • Protein
    Protein
    Published protein sequences
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links
  • Taxonomy
    Taxonomy
    Related taxonomy entry
  • Taxonomy Tree
    Taxonomy Tree

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...